THERAPEUTIC CLEARANCE OF COMPLEMENT C5A

拟议研究的总体目标是提供一个具体的， 在有成年风险的患者中灭活C5a的实用方法 呼吸窘迫综合征（ARDS）。 C5a是一个关键的贡献者， 可能是ARDS病理过程中的必要因素。 文献中提到的能够灭活C5a的蛋白质 特征不明显。 Synergen的科学家们选择了一个 从人体组织中分离这些蛋白质， 它的行动方式。 基于该生物活性的测定将 用于纯化、表征、克隆和表达蛋白， 重组DNA技术。 通过降低C5a在 对于有ARDS风险的患者，我们预计这种蛋白质将提供 一种用于预防或改善糖尿病的有用的治疗剂， 病理

The overall goal of the proposed research is to provide a specific, practical means for inactivating C5a in patients at risk of adult respiratory distress syndrome (ARDS). C5a is a key contributory, possibly necessary factor in the pathological course of ARDS. The proteins capable of inactivating C5a noted in the literature are poorly characterized. Synergen's scientists have selected one of these proteins to isolate from human tissue, then characterize its mode of action. An assay based on this biological activity will be used to purify, characterize, clone and express the protein by recombinant DNA technologies. By reducing the action of C5a in patients at risk for ARDS, we expect that the protein will provide a useful therapeutic agent for prevention or amelioration of the pathology.